相关实验视频

Updated: May 11, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

新辅助 pembrolizumab 坚持对三阴性乳腺癌病理完整反应的影响:现实世界的分析

Alexis LeVee¹, Megan Wong¹, Sarah Flores¹

¹Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

|April 24, 2024

概括

年龄较小和完成至少8个周期的 pembrolizumab (pembro) 与新辅助化疗 (NAC) 在早期三阴性乳腺癌 (TNBC) 患者中改善了病理完整反应 (pCR). 这些因素是优化TNBC治疗策略的关键.

科学领域:

在瘤学瘤学.
临床研究临床研究
乳腺癌治疗方法乳腺癌治疗方法

背景情况:

与新辅助化疗 (NAC) 结合的 pembrolizumab (pembro) 是KEYNOTE-522后早期三阴性乳腺癌 (TNBC) 的标准.
最佳的TNBC治疗策略,包括患者选择和 pembro 治疗方案的具体情况,需要进一步澄清.

研究的目的:

确定与早期TNBC中NAC加 pembrolizumab反应相关的现实世界的临床特征和治疗变量.
确定在接受NAC和pembrolizumab的TNBC患者中预测病理完整反应 (pCR) 的因素.

主要方法:

早期TNBC患者接受NAC加Pembrolizumab治疗的回顾性分析 (2020年2月至2023年9月).
使用单变量和多变量逻辑回归分析来确定与pCR相关的因素.
考克斯的比例危险模型评估了无侵袭性疾病和整体存活率的预测因素.

主要成果:

在118名患者中,75人 (63.6%) 实现了pCR.
单变量分析显示诊断时的年龄,Ki-67,pembrolizumab/NAC的持续时间,以及周期数与pCR相关.
多变量分析确定年龄较小 (<55岁) 和完成至少8个勃利祖马布治疗周期作为pCR的显著预测因素.

结论:

诊断时年轻的年龄和完成至少8次班布罗利祖马布治疗周期与接受NAC的TNBC患者的pCR改善有关.
这些发现为优化真实世界TNBC环境中的 pembrolizumab 治疗策略提供了洞察力.

关键词:

免疫疗法免疫疗法新辅助性化疗是一种新辅助性化疗.病理学的完整反应.这就是Pembrolizumab.三重阴性乳腺癌是什么

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...